Mass-spectrometry analysis of histone post-translational modifications in pathology tissue using the PAT-H-MS approach by R. Noberini et al.
Contents lists available at ScienceDirect
Data in Brief
Data in Brief 7 (2016) 188–194http://d
2352-34
(http://c
n Co-c
E-mjournal homepage: www.elsevier.com/locate/dibData ArticleMass-spectrometry analysis of histone
post-translational modiﬁcations in pathology
tissue using the PAT-H-MS approach
Roberta Noberini a,n, Giancarlo Pruneri b,c, Saverio Minucci d,e,f,
Tiziana Bonaldi d,n
a Center for Genomic Science of IIT@SEMM, Istituto Italiano di Tecnologia, Via Adamello 16, 20139 Milan, Italy
b School of Medicine, University of Milan, 20122 Milan, Italy
c Biobank for Translational Medicine Unit, Department of Pathology, European Institute of Oncology, Via
Ripamonti 435, 20141 Milan, Italy
d Department of Experimental Oncology, European Institute of Oncology, Via Adamello 16, 20139 Milan, Italy
e Drug Development Program, European Institute of Oncology, Via Adamello 16, 20139 Milan, Italy
f Department of Bioscience, University of Milan, 20133 Milan, Italya r t i c l e i n f o
Article history:
Received 19 November 2015
Received in revised form
9 February 2016
Accepted 9 February 2016
Available online 16 February 2016
Keywords:
Mass spectrometry
Proteomics
Epigenetics
Histone posttranslational modiﬁcations
Formalin-ﬁxed parafﬁn embedded tissues
Biomarker
Breast cancerx.doi.org/10.1016/j.dib.2016.02.028
09/& 2016 The Authors. Published by Else
reativecommons.org/licenses/by/4.0/).
orresponding authors.
ail addresses: roberta.noberini@iit.it (R. Noba b s t r a c t
Aberrant histone post-translational modiﬁcations (hPTMs) have
been implicated with various pathologies, including cancer, and
may represent useful epigenetic biomarkers. The data described
here provide a mass spectrometry-based quantitative analysis of
hPTMs from formalin-ﬁxed parafﬁn-embedded (FFPE) tissues,
from which histones were extracted through the recently devel-
oped PAT-H-MS method. First, we analyzed FFPE samples from
mouse spleen and liver or human breast cancer up to six years old,
together with their corresponding fresh frozen tissue. We then
combined the PAT-H-MS approach with a histone-focused version
of the super-SILAC strategy-using a mix of histones from four
breast cancer cell lines as a spike-in standard- to accurately
quantify hPTMs from breast cancer specimens belonging to dif-
ferent subtypes. The data, which are associated with a recent
publication (Pathology tissue-quantitative mass spectrometry
analysis to proﬁle histone post-translational modiﬁcation patternsvier Inc. This is an open access article under the CC BY license
erini), tiziana.bonaldi@ieo.eu (T. Bonaldi).
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R. Noberini et al. / Data in Brief 7 (2016) 188–194 189in patient samples (Noberini, 2015) [1]), are deposited at the
ProteomeXchange Consortium via the PRIDE partner repository
with the dataset identiﬁer PXD002669.
& 2016 The Authors. Published by Elsevier Inc. This is an open
access article under the CC BY license
(http://creativecommons.org/licenses/by/4.0/).Speciﬁcations tableubject area Biology
ore speciﬁc sub-
ject areaProteomicsype of data Mass spectrometry raw data and MaxQuant search results
ow data was
acquiredData dependent LC-MS/MS acquired on a Q Exactive instrument (Thermo Fisher
Scientiﬁc) coupled to a ultra nanoﬂow high-performance liquid chromatography
(HPLC) system (EASY-nLC™ 1000, Thermo Fisher Scientiﬁc)ata format MS-RAW ﬁles, experimental design and.txt and.apl output ﬁles generated by the
MaxQuant softwarexperimental
factorsHistones were puriﬁed from frozen and FFPE mouse and human samplesxperimental
featuresPuriﬁed/enriched histones were in-gel digested through an Arg-C-like digestion
and subjected to LC/MS/MS analysis. A heavy-labelled histone spike-in standard
was used to quantitate hPTMs in human samplesata source
locationMilan, Italy, European Institute of Oncologyata accessibility Data have been deposited to the ProteomeXchange Consortium via the PRIDE
partner repository with the dataset identiﬁer PXD002669Value of the data
 Analysis of hPTM marks in FFPE tissue of different origin (mouse spleen and liver and human breast
cancer biopsies) and their corresponding fresh-frozen tissues.
 A histone-focused version of the super-SILAC approach used to accurately quantitate hPTMs in breast
cancer samples.
 Quantitative analysis of hPTMs in 20 breast cancer samples belonging to different subtypes, whose
immunoproﬁle and staging are provided
 The data can be used to proﬁle less common PTMs, such as K-ubiquitylation, R-methylation, K-croto-
nylation, as well as histone H3 variants, among different cancer subtypes.1. Data
This proteomics dataset comprise LC-MS/MS raw ﬁles obtained from bottom-up MS analysis of histone
H3 and H4 isolated using different procedures (Fig. 1) from mouse and human tissues, which were either
stored as frozen samples or formalin-ﬁxed and parafﬁn-embedded (FFPE). The dataset also includes the
output ﬁles of the database search for common hPTMs and formalin-induced modiﬁcations.2. Experimental design, materials and methods
The data correspond to three main experiments (Tables 1 and S1): (1) analysis of FFPE and cor-
responding frozen tissue in mouse spleen or liver, stored for few weeks up to 6 years, (2) analysis of
Table 1
Sample analyzed and experimental designn
Main
experiment
Species Tissue Type of
storage
Length of
storage
Replicates Histone
analyzed
Histone
isolation
protocol
Super-
SILAC spike
in
Experiment 1:
fresh-frozen
and FFPE
mouse samples
mouse spleen frozen few weeks 2 biological H3, H4 1 no
FFPE 2 biological 3 no
liver frozen few weeks 2 technical 1 no
FFPE 2 technical 3 no
spleen frozen 6 years 2 technical 1 no
FFPE 2 technical 3 no
Experiment 2:
fresh-frozen
and FFPE
human breast
cancer biopsies
human breast cancer
(biopsy 1)
frozen few
months
3 technical H3 2 yes
FFPE 3 technical 3 yes
breast cancer
(biopsy 2)
frozen 3 technical 2 yes
FFPE 3 technical 3 yes
breast cancer
(biopsy 3)
frozen 3 technical 2 yes
FFPE 3 technical 3 yes
Experiment 3:
FFPE human
breast cancer
biopsies
belonging to
different
subtypes
human breast cancer -
Luminal A
FFPE few
months
5 patients H3 3 yes
breast cancer -
Luminal B
FFPE 5 patients 3 yes
breast cancer -
Triple Negative
FFPE 5 patients 3 yes
breast cancer -
HER2 positive
FFPE 5 patients 3 yes
n
see Table S1 for related raw ﬁles.
Fig. 1. Scheme of protocols used to isolate histones from different types of samples. Protocol 1: Frozen mouse liver and spleen.
Protocol 2: Frozen human breast cancer tissue. Protocol 1: FFPE tissues (mouse and human). Protocol 4: Heavy-labeled breast
cancer cell lines for super-SILAC mix.
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(3) analysis of 20 FFPE breast cancer tissues belonging to different subtypes (Luminal A-like, Luminal
B-like, Triple Negative and HER2 positive). The analysis of breast cancer samples was carried out using
a super-SILAC mix of heavy-labeled histones from 4 breast cancer cell lines as internal standard.
2.1. Preparation of fresh-frozen and FFPE tissues
Spleen tissue was obtained from leukemic mice as previously described [2] and divided into
two portions. One portion was washed and homogenized in ice-cold phosphate buffered saline
Table 2
Breast cancer biopsies
Breast cancer biopsy Subtypea Immunoproﬁleb pTNMc Grading
ER (%) PR (%) HER2 Ki-67 (%)
1 Luminal B 90 90 60%(þ) 25 pT2N1a G2
2 Luminal A 90 90 – 17 pT1cN0M0 G2
3 Luminal B 50 – 80% (þþ) 22 pT1cN0M0 G3
1 (LuA) Luminal A 95 95 – 15 PT1c pNx G2
2 (LuA) Luminal A 95 95 – 12 PT2(is) pNza G2
3 (LuA) Luminal A 90 90 80% (þ) 18 PT2 Pnd (sn) G2
4 (LuA) Luminal A 495 495 60% (þ) 10 PT1a G1
5 (LuA) Luminal A 90 80 30% (þ) 13 PT2 Pn3a G2
6 (TN) Triple Negative – – – 70 PT2 Pn1a G3
7 (TN) Triple Negative – – – 75 PT1C Pn0 (sn) G3
8 (TN) Triple Negative – – – 60 PT2 Pn1a G3
9 (TN) Triple Negative – – – 70 PT2 Pn1a G3
10 (TN) Triple Negative – – 30% (þ) 16 PT1C Pn1mi (sn) G2
11 (HER) HER þ – – 90% (þþþ) 30 PT1C Pn0 (sn) G3
12 (HER) HER þ – – 495% (þþþ) 85 ypT3 ypN2a
13 (HER) HER þ – – 495% (þþþ) 46 PT1C Pn0 G3
14 (HER) HER þ – – 495% (þþþ) 32 rpT1c rpNx G3
15 (HER) HER þ – – 495% (þþþ) 75 Pt3 (m) Pn0(sn) G3
16 (LuB) Luminal B 95 20 – 45
17 (LuB) Luminal B 95 80 70% (þþ) 55 PT2 (m) Pn1a G3
18 (LuB) Luminal B 95 95 65% (þ) 25 PT2 (m) PN0 G3
19 (LuB) Luminal B 95 10 40% (þ) 29 Pt1c pNx G3
20 (LuB) Luminal B 95 95 60% (þ) 26 PT1b Pnd(sn) G3
a Based on the Ki-67 labeling index value.
b ER: estrogen receptor, PR: progesteron receptor, HER2: human epidermal growth factor receptor 2.
c pTNM: pathological tumor-node-metastasis.
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obtain spleen cells that were counted, pelleted by centrifugation, frozen and stored at 80 °C until
use. The other half of the spleen was rapidly washed in PBS and incubated for 16 h at room tem-
perature in 4% paraformaldehyde. The ﬁxed spleen was dehydrated with increasing concentrations
of ethanol (70%, 80%, 90% and 100%) and then included in parafﬁn using a tissue processor (Leica
ASP300). Frozen cells and FFPE samples were prepared similarly from mouse liver. Experimental
procedures involving animals complied with the National Institutes of Health guide for the care and
use of Laboratory animals (NIH Publications no. 8023, revised 1978), and were approved by the
Institutional Ethical Committee.
Breast cancer specimens were obtained from 23 patients with duct invasive carcinoma not
otherwise speciﬁed (Table 2), who were subjected to mastectomy or breast conserving surgery. The
patients provided informed consent and this study was approved by the Ethical Committee of the
European Institute of Oncology. Tumor samples were collected and snap frozen or ﬁxed 4% formalin
and embedded in parafﬁn. The immunoproﬁle of the samples was determined by immunohis-
tochemistry, using the anti-ER/PgR (PharmDX, Dako), the Her-2 (Herceptest, Dako) and the anti-Ki-67
antibody MIB-1. Breast cancer subtypes were deﬁned according to the 2013 S. Gallen consensus
conference recommendations: Luminal A-like: ER and/or PgR(þ), HER2(), Ki67o20%; Luminal
B-like: ER and/or PgR(þ), HER2(), Ki67Z20; Triple Negative: ER, PgR and HER2(), irrespective of
Ki67 score; HER2-positive: HER2(þ), irrespective of ER, PgR or Ki67. ER/PgR positivity was deﬁned
asZ1% of immunoreactive neoplastic cells; HER2 positivity was deﬁned as410% of neoplastic cells
with strong and continuous staining of the cell membrane (3þ by immunohistochemistry) and/or
ampliﬁed by in situ hybridization techniques.
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Cells were obtained from fresh mouse spleen and liver as described above and histones were
isolated as previously described [3]. Brieﬂy, 30106 cells were resuspended in lysis buffer (10%
sucrose; 0.5 mM EGTA, pH 8.0; 15 mM NaCl; 60 mM KCl; 15 mM HEPES; 0.5% Triton; 0.5 mM PMSF;
1 mM DTT; 5 mM NaF; 5 mM Na3VO4; 5 mM Na-butyrate; protease inhibitors) and nuclei were iso-
lated by centrifugation on a sucrose cushion. Histones were extracted by overnight incubation in
0.4 N HCl at 4 °C and dialyzed against 100 mM CH3COOH, using dialysis membranes with a 6–8 kDa
cutoff (Spectrumlab). The dialyzed samples were lyophilized and stored at 80 °C.
2.3. Histone isolation from fresh-frozen human breast cancer tissues (Fig. 1, protocol 2)
20–70 mg of frozen breast cancer tissue were thawed on ice, cut in small pieces with scissors and
then homogenized with a Dounce homogenizer in PBS containing 0.1% Triton X-100 and protease
inhibitors. Tissue debris were removed by ﬁltration through a 100 μm cell strainer and nuclei were
isolated through a 10 min centrifugation at 2300 g. Nuclei were resuspended in 100–200 μl of the
same buffer including 0.1% SDS and incubated with 250 U of benzonase (Merk Millipore) for few
minutes at 37 °C to digest nucleic acids. Histone concentration and purity was assessed using the
Bradford protein assay kit (Thermo Fisher Scientiﬁc) and SDS-PAGE.
2.4. Histone isolation from FFPE tissues (PAT-H-MS, Fig. 1, protocol 3)
Four 10-μm tissue sections were deparafﬁnized by repeating 5 times addition of 1 ml of hystolemon
(Dasit Group Carlo Erba), vortexing for 30 s and centrifuging at 18,000 g for 3 min. The samples were
then rehydrated in decreasing concentrations of ethanol (100%, 95%, 70%, 50%, 20% and water) for 3 min
at room temperature, followed by a 35 min centrifugation at 18,000 g. Rehydrated FFPE sections
were permeabilized in 0.5 ml of Tris-buffered saline (TBS) containing protease inhibitors and 0.5%
Tween20 for 20 min at room temperature in a rotating platform, followed by a 5 min centrifugation at
18,000 g. The samples were resuspended in 200 μL of 20 mM Tris pH 7.4 containing 2% SDS and
sonicated in a Branson Digital Soniﬁer 250 with a 3 mm microtip until all tissues pieces were homo-
genized. Proteins were extracted and de-crosslinked with a 45 min incubation at 95 °C, followed by a
4 h incubation at 65 °C. After estimating the protein concentration with the Biorad DC protein assay kit
(Biorad), 16–20 μg of proteins were run on a 17% SDS-PAGE gel together with known amounts of
recombinant histone H3.1, which was used as a standard to estimate histone concentration.
2.5. Histone isolation from breast cancer cell lines (Fig. 1, Protocol 4)
MDA-MB-231, MDA-MB-468, MDA-MB-453 and MDA-MB-361 (ATCC) were grown in SILAC-DMEM
(Euroclone) supplemented with 2 mM L-glutamine, 146 mg/l of lysine (Sigma-Aldrich), 84 mg/l
L-13C615N4-arginine (Arg-10, Sigma-Aldrich), 10% dialyzed serum (Life Technologies) and penicillin/
streptomycin for approximately 8 doublings to obtain complete labeling. Histones were isolated using
the same procedure described for cells obtained from fresh-frozen mouse tissues. Equal amounts of
histones from each cell line were mixed, aliquoted, lyophilized and stored at 80 °C until use.
2.6. Histone digestion
Approximately 4–5 μg of histones per run per sample were separated on a 17% SDS-PAGE gel and bands
corresponding to histones H3 and H4 were excised and in-gel digested as previously described [1,3]. Brieﬂy,
gel bands were cut in pieces, destained and in-gel chemically alkylated with D6-acetic anhydride (Sigma-
Aldrich) 1:9 in 1 M NH4HCO3, using CH3COONa as catalyzer. After a 3 h incubation at 37 °C, the gel slices
were washed with NH4HCO3, followed by ACN at increasing percentages (from 50 to 100). The in-gel
digestionwas performed overnight with 100 ng/μL trypsin (Promega) in 50 mMNH4HCO3 at 37 °C, in order
to obtain an “Arg-C like” in-gel digestion. Digested peptides were extracted using 5% formic acid alternated
with ACN 100%. In SILAC experimental set-ups, unlabeled and heavy-labeled histones were mixed in equal
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and concentrated using a combination of reversed-phase C18/C and strong cation exchange (SCX) chro-
matography on handmade nanocolumns (StageTips). Digested peptides were then eluted with 80% ACN/
0.5% acetic acid and 5% NH4OH/30% methanol from C18/C and SCX StageTips, respectively. Eluted peptides
were lyophilized, resuspended in 1% TFA, pooled and subjected to LC-MS/MS analysis.2.7. LC-MS/MS
Peptide mixtures were separated by reversed-phase chromatography on an in-house-made 25 cm col-
umn (outer diameter 350 μm, inner diameter 75 μm, 1.9 μm ReproSil, Pur C18AQ medium), using a ultra
nanoﬂow high-performance liquid chromatography (HPLC) system (EASY-nLC™ 1000, Thermo Fisher Sci-
entic) connected online to a Q Exactive instrument (Thermo Fisher Scientiﬁc) through a nanoelectrospray ion
source. Solvent Awas 0.1% formic acid (FA) in ddH2O and solvent B was 80% ACN plus 0.1% FA. Peptides were
injected in an aqueous 1% TFA solution at a ﬂow rate of 500 nl/min and were separated with a 100min
linear gradient of 0–40% solvent B, followed by a 5min gradient of 40–60% and a 5min gradient of 60–95%
at a ﬂow rate of 250 nl/min. The Q Exactive instrument was operated in the data-dependent acquisition
(DDA) mode to automatically switch between full scan MS and MS/MS acquisition. Survey full scan MS
spectra (m/z 300–1650) were analyzed in the Orbitrap detector with resolution of 35,000 atm/z 400. The ﬁve
most intense peptide ions with charge statesZ2 were sequentially isolated to a target value for MS1 of
3106 and fragmented by HCD with a normalized collision energy setting of 25%. The maximum allowed
ion accumulation times were 20ms for full scans and 50ms for MS/MS and the target value for MS/MS was
set to 1106. The dynamic exclusion time was set to 20 s and the standard mass spectrometric conditions
for all experiments were as follows: spray voltage of 2.4 kV, no sheath and auxiliary gas ﬂow.2.8. Data analysis
Acquired RAW data were analyzed by the MaxQuant software v.1.3.0.5 with the Andromeda search
engine [4]. The Uniprot MOUSE 1301 and HUMAN 1301 databases were used for peptide identiﬁcation.
Enzyme speciﬁcity was set to Arg-C. The estimated false discovery rate of all peptide identiﬁcations was
set at a maximum of 1%. The mass tolerance was set to 6 ppm for precursor and fragment ions. Three
missed cleavages were allowed, and the minimum peptide length was set to 6 amino acids. Variable
modiﬁcations were lysine D3-acetylation (þ45.0294 Da), lysine monomethylation (þ59.0454 Da, cor-
responding to the sum of D3-acetylation (þ45.0294) and monomethylation (þ14.016)), dimethylation
(þ28.031 Da), trimethylation (þ42.046 Da), and lysine acetylation (þ42.010 Da). The raw data were
analyzed through multiple parallel MaxQuant jobs, setting different combinations of variable mod-
iﬁcations: (1) D3-acetylation, lysine monomethylation with D3-acetylation, dimethylation and lysine
acetylation, (2) D3-acetylation, lysine monomethylation with D3-acetylation, dimethylation and tri-
methylation, (3) D3-acetylation, lysine monomethylation with D3-acetylation, trimethylation and lysine
acetylation (4, only for mouse samples) D3-acetylation, formylation (þ27.9949 Da), methylene adducts
(þ12 Da) and methylol adducts (þ30.0106 Da). For SILAC experiments, Arg10 was selected as heavy
label (multiplicity¼2). Raw data corresponding to each experiment are reported in Table S1.Acknowledgments
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